News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
259,320 Results
Type
Article (13832)
Company Profile (293)
Press Release (245195)
Section
Business (79305)
Career Advice (147)
Deals (13176)
Drug Delivery (31)
Drug Development (50264)
Employer Resources (31)
FDA (5668)
Job Trends (5110)
News (144022)
Policy (10013)
Tag
Academia (901)
Alliances (21440)
Alzheimer's disease (731)
Approvals (5632)
Artificial intelligence (61)
Bankruptcy (97)
Best Places to Work (4473)
Biotechnology (241)
Breast cancer (57)
Cancer (616)
Cardiovascular disease (52)
Career advice (128)
CAR-T (48)
Cell therapy (157)
Clinical research (39634)
Collaboration (207)
Compensation (86)
COVID-19 (999)
C-suite (60)
Cystic fibrosis (61)
Data (668)
Diabetes (66)
Diagnostics (1195)
Earnings (28746)
Events (46628)
Executive appointments (157)
FDA (5920)
Funding (211)
Gene editing (52)
Gene therapy (130)
GLP-1 (295)
Government (1063)
Healthcare (6528)
Infectious disease (1029)
Inflammatory bowel disease (89)
IPO (7169)
Job creations (859)
Job search strategy (124)
Layoffs (182)
Legal (1372)
Lung cancer (104)
Manufacturing (68)
Medical device (2548)
Medtech (2549)
Mergers & acquisitions (6091)
Metabolic disorders (209)
Neuroscience (913)
NextGen Class of 2024 (1997)
Non-profit (842)
Northern California (833)
Obesity (120)
Opinion (90)
Parkinson's disease (55)
Patents (47)
People (24905)
Pharmaceutical (48)
Phase I (13939)
Phase II (18427)
Phase III (11694)
Pipeline (216)
Postmarket research (846)
Preclinical (5890)
Radiopharmaceuticals (203)
Rare diseases (145)
Real estate (1409)
Regulatory (8169)
Research institute (930)
Southern California (771)
Startups (1963)
United States (6894)
Vaccines (156)
Weight loss (75)
Date
Today (179)
Last 7 days (598)
Last 30 days (1997)
Last 365 days (20687)
2024 (18049)
2023 (22412)
2022 (26822)
2021 (27806)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16777)
Australia (2821)
California (1884)
Canada (659)
China (142)
Colorado (70)
Connecticut (74)
Europe (36113)
Florida (200)
Georgia (55)
Illinois (114)
Indiana (53)
Kansas (55)
Maryland (280)
Massachusetts (1561)
Michigan (46)
Minnesota (85)
New Jersey (503)
New York (559)
North Carolina (384)
Northern California (833)
Ohio (73)
Pennsylvania (389)
South America (207)
Southern California (771)
Texas (192)
Washington State (201)
259,320 Results for "cyteir therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq - March 07, 2024
Cyteir Therapeutics, Inc. announced that it has formally notified The Nasdaq Stock Market of its intent to delist the Company’s common stock from the Nasdaq Global Select Market.
March 7, 2024
·
2 min read
Genetown
Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution
Cyteir Therapeutics, Inc. (“Cyteir” or the “Company”) (Nasdaq: CYT) today announced that it is discontinuing all development of CYT-0851, its investigational monocarboxylate transporter inhibitor.
June 30, 2023
·
8 min read
Business
Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a clinical stage oncology company, today reported financial results for the first quarter ended March 31, 2023 and provided an update on recent operational highlights.
May 10, 2023
·
7 min read
Business
Cyteir Therapeutics Promotes David Gaiero to Chief Financial Officer
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) a clinical stage oncology company today announced the promotion of David Gaiero to Chief Financial Officer (CFO).
February 6, 2023
·
2 min read
Business
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a clinical stage oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on recent operational highlights.
March 23, 2023
·
8 min read
Genetown
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) today announced the strategic prioritization of clinical development of CYT-0851, an investigational monocarboxylate transporter inhibitor, as a potential combination therapy for the treatment of ovarian cancer.
January 19, 2023
·
7 min read
Business
Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the third quarter ended September 30, 2022 and provided an update on recent operational highlights.
November 7, 2022
·
8 min read
Business
Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent operational highlights.
August 8, 2022
·
9 min read
Genetown
Cyteir Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President and Chief Executive Officer, Markus Renschler, MD, will participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 9, 2022.
August 1, 2022
·
1 min read
Genetown
Cyteir Therapeutics to Participate in the 2022 Jefferies Healthcare Conference
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that Markus Renschler, MD, President and Chief Executive Officer will participate in a presentation at the 2022 Jefferies Healthcare Conference.
May 31, 2022
·
1 min read
1 of 25,932
Next